Duloxetine Capsule, Delayed Release
Product Images NDC 60760-461

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 60760-461). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by St. Mary's Medical Park Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (Duloxetine Structure)

Chemical structure diagram of the active ingredient Duloxetine, showing its molecular composition including a thiophene ring, a naphthalene moiety, and an amine group with hydrochloride.*

FDA Label Image

Figure1 (Duloxetine Fig1)

A Kaplan-Meier curve chart showing the proportion of patients with relapse over time in days from randomization to relapse for two treatment groups: placebo (dashed line) and Duloxetine (solid line). The vertical axis represents the proportion of patients with relapse, ranging from 0 to 1, while the horizontal axis shows time in days up to 250.*

FDA Label Image

Figure2 (Duloxetine Fig2)

A Kaplan-Meier survival curve plot showing the proportion of patients with relapse over time from randomization to relapse (in days). Two treatment groups are represented: Duloxetine (solid line) and Placebo (dashed line). The x-axis ranges from 0 to 300 days, and the y-axis shows the proportion of patients relapsed from 0.0 to 1.0.*

FDA Label Image

Figure3 (Duloxetine Fig3)

A line graph comparing the percentage of patients improved by different doses of Duloxetine versus placebo. The x-axis represents percent improvement in pain from baseline (0% to 100%), and the y-axis shows the percentage of patients improved. Lines represent Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, Duloxetine 20 mg once daily, and placebo, illustrating patient response across varying pain improvement levels.*

FDA Label Image

Figure4 (Duloxetine Fig4)

A line graph presenting the percentage of patients improved versus percent improvement in pain from baseline. The graph compares three groups: Duloxetine 60 mg twice daily (BID), Duloxetine 60 mg once daily (QD), and placebo, showing trends in patient pain improvement across different percentage improvements.*

FDA Label Image

Figure5 (Duloxetine Fig5)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. It compares three groups: Duloxetine 60mg twice daily, Duloxetine 60mg once daily, and placebo. The graph depicts a higher percentage of patient improvement with Duloxetine doses compared to placebo across various pain improvement thresholds.*

FDA Label Image

Figure6 (Duloxetine Fig6)

A line graph showing the percentage of patients improved against the percent improvement in pain from baseline. The graph compares Duloxetine at doses 120 mg once daily, 60 mg once daily, 20 mg once daily, and placebo. All Duloxetine doses show higher patient improvement percentages than placebo across increasing pain improvement levels.*

FDA Label Image

Figure7 (Duloxetine Fig7)

A line graph showing percentage of patients improved versus percent improvement in pain from baseline. Two data series are compared: Duloxetine 60 mg once daily and placebo, depicting higher improvement percentages for duloxetine across pain improvement ranges.*

FDA Label Image

Figure8 (Duloxetine Fig8)

This line graph compares the percentage of patients improved at various levels of pain improvement from baseline (BOCF) between Duloxetine 60/120 mg once daily and placebo. The x-axis represents percent improvement in pain, and the y-axis shows the percentage of patients improved. Duloxetine shows a generally higher percentage of patient improvement across pain improvement levels compared to placebo.*

FDA Label Image

Figure9 (Duloxetine Fig9)

A line graph comparing the percentage of patients improved in pain from baseline (BOCF) between placebo and Duloxetine 60 mg once daily. The x-axis represents percent improvement in pain from baseline ranging from >0 to 100%. The y-axis shows the percentage of patients improved from 0 to 100%. The Duloxetine treatment group consistently shows a higher percentage of patients improved across varying levels of pain improvement compared to placebo.*

FDA Label Image

Figure10 (Duloxetine Fig10)

A line chart comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) for Duloxetine 60/120 mg once daily and placebo groups. The chart shows a higher percentage of patient improvement across various pain improvement thresholds for Duloxetine compared to placebo.*

FDA Label Image

461 (Duloxetine Dr 30mg 60ct 60760 461 60)

Duloxetine Delayed-Release Capsules 30 mg label shows the prescription drug with dosage form as delayed-release capsules. The label notes 60 capsules per package and includes information about the active ingredient, duloxetine hydrochloride USP equivalent to 30 mg duloxetine. It states storage instructions at 25°C and directions to keep the container tightly closed and out of reach of children. The label indicates it is marketed by Ajanta Pharma USA Inc and packaged by St. Mary's Medical Park Pharmacy in Oro Valley, AZ.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.